Order a test kit
Precise™ Tumor† is a next-generation sequencing (NGS) assay with hybrid capture model consisting of DNA- and RNA-based testing which detects Single-Nucleotide Variants (SNV), Insertion-Deletion Mutations (INDELs), Copy Number Variants (CNV), and fusions in solid tumors.
You can download additional resources for Precise Tumor HERE
Using tumor testing procedures you are familiar with in an innovative and comprehensive way, Precise Tumor testing will allow you to save time, gain confidence, and arm yourself with the information you need to help your patients. Also included in Precise Tumor testing is optional enrollment in our treatment registry.
Actionable: 500+ solid tumor-related genes with broad coverage of key guidelines and clinical trials for multiple solid tumor types.
Key Immuno-oncology biomarkers:
Clinically Validated and Comprehensive genomic coverage necessary for accurate selection of FDA-approved targeted and immunotherapy (IO), biomarkers while also evaluating, while also evaluating many genes relevant to early phase drug development efforts that may have future clinical applications in all solid tumors1.
Accurate: Sensitivity: 98.91% Specificity >99.99% using orthogonal methods, including DNA- and RNA-based next generation targeted exome sequencing with full coverage of all exons. Accurately measures TMB, microsatellite instability, SNVs, indels, copy-number/structural variation and gene fusions when compared to WGS and orthogonal technologies2.
Cutting edge technologies: Fusions and splice variants assessed via RNA analysis, which may detect more actionable fusions and splice variants, as compared to DNA tests only3-6.
† Precise Tumor is powered by Intermountain Precision Genomics®, a service of Intermountain® Healthcare
*See Precise Tumor Pathology Guide for additional details
Download full list of biomarkers
Download detailed aid
Download pathology guide
Download provider guide
Ideal specimen are chemotherapy-naïve tumors from primary debulking surgery or biopsy.
If patient has received neoadjuvant therapy, chemotherapy-treated tumors from primary debulking surgery may be submitted, but chemotherapy-naïve tumor from biopsy is preferred.
If debulking doesn’t provide sufficient tumor, pre-treatment biopsy samples should be considered.
Cytology cell blocks (e.g., ascites fluid) are acceptable but tumor content must exceed 30%. Unfixed cytology samples are not appropriate for genomic testing.
* Pre-treatment biopsy samples should be considered in patients with complete or near-complete treatment response.
Labs need to strike the appropriate balance between cutting enough tissue for diagnosis and preserving enough tissue for ancillary testing. Myriad will send back any remaining tissue block as soon as the test result is reported. Pre-cut unstained slides will not be returned.
Myriad needs the contact information you provide to us to contact you about our products and services. You may
unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your